Overview

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood

Status:
Not yet recruiting
Trial end date:
2022-12-16
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to investigate the induction effect of multiple doses of BI 1015550 on the pharmacokinetics of the sensitive CYP3A4 substrate midazolam.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Midazolam